Literature DB >> 26940927

Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation.

Gregory A Roth1, Jeanne E Poole2, Rebecca Zaha3, Weiping Zhou3, Jonathan Skinner4, Nancy E Morden5.   

Abstract

BACKGROUND: Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) is recommended before primary prevention implantable cardioverter-defibrillator (ICD) placement. Adherence to this recommendation and associated outcomes are unknown.
OBJECTIVES: This study examined the use of GDMT (≥1 prescription filled for both a renin-angiotensin inhibitor [RAI] and a heart failure-approved beta-blocker [HFBB]) within 90 days before primary prevention ICD placement in patients with HFrEF.
METHODS: Data from the National Cardiovascular Data Registry ICD Registry were merged with a 40% random sample of Medicare administrative data. Prescription fills for recipients of primary prevention ICD between 2007 and 2011 were examined, analyzing GDMT overall and for each U.S. hospital referral region. We identified characteristics associated with GDMT and the association with 1-year mortality.
RESULTS: Among 19,733 patients with HFrEF and primary prevention ICD, 61.1% filled any GDMT before implantation. Across hospital referral regions, GDMT was applied in 51% to 71%. The strongest predictors of any GDMT included absence of chronic renal disease or nonsustained ventricular tachycardia, low-income prescription benefits subsidy, and less recent left ventricular ejection fraction evaluation. Patients receiving GDMT versus those without had a lower 1-year mortality rate after ICD implantation (11.1% vs. 16.2%), even after adjustment for comorbidities, left ventricular ejection fraction, and functional heart failure class.
CONCLUSIONS: Rates of GDMT for HFrEF before primary prevention ICD implantation were low, and failure to achieve GDMT was associated with significantly decreased 1-year survival.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  defibrillator; health services research; heart failure

Mesh:

Year:  2016        PMID: 26940927      PMCID: PMC4780248          DOI: 10.1016/j.jacc.2015.12.046

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  13 in total

1.  Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry.

Authors:  Amy Leigh Miller; Yongfei Wang; Jeptha Curtis; Frederick A Masoudi; Alfred E Buxton; Tracy Y Wang
Journal:  Arch Intern Med       Date:  2011-11-14

2.  2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

3.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.

Authors:  Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; David P Faxon; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick A Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2008-05-27       Impact factor: 24.094

4.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

5.  A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement.

Authors:  Paul A Heidenreich; Vivian Tsai; Jeptha Curtis; Yongfei Wang; Mintu P Turakhia; Frederick A Masoudi; Paul D Varosy; Mary K Goldstein
Journal:  Am Heart J       Date:  2015-01-07       Impact factor: 4.749

6.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.

Authors:  M Packer; G V Antonopoulos; J A Berlin; J Chittams; M A Konstam; J E Udelson
Journal:  Am Heart J       Date:  2001-06       Impact factor: 4.749

8.  HFSA 2010 Comprehensive Heart Failure Practice Guideline.

Authors:  JoAnn Lindenfeld; Nancy M Albert; John P Boehmer; Sean P Collins; Justin A Ezekowitz; Michael M Givertz; Stuart D Katz; Marc Klapholz; Debra K Moser; Joseph G Rogers; Randall C Starling; William G Stevenson; W H Wilson Tang; John R Teerlink; Mary N Walsh
Journal:  J Card Fail       Date:  2010-06       Impact factor: 5.712

9.  Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures.

Authors:  Paul J Hauptman; Jason P Swindle; Frederick A Masoudi; Thomas E Burroughs
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-03-02

10.  Statin adherence and risk of accidents: a cautionary tale.

Authors:  Colin R Dormuth; Amanda R Patrick; William H Shrank; James M Wright; Robert J Glynn; Jenny Sutherland; M Alan Brookhart
Journal:  Circulation       Date:  2009-04-06       Impact factor: 29.690

View more
  14 in total

1.  Moving Beyond the Hospital.

Authors:  Cian P McCarthy; Muthiah Vaduganathan; Zirui Song
Journal:  Circulation       Date:  2018-11-13       Impact factor: 29.690

Review 2.  Improving Provider Adherence to Guideline Recommendations in Heart Failure.

Authors:  Katherine E Di Palo; Ileana L Piña; Hector O Ventura
Journal:  Curr Heart Fail Rep       Date:  2018-12

3.  Response to cardiac resynchronization therapy in non-ischemic cardiomyopathy is unrelated to medical therapy.

Authors:  Gregory Sinner; Hesham R Omar; You W Lin; Samy C Elayi; Maya E Guglin
Journal:  Clin Cardiol       Date:  2018-12-15       Impact factor: 2.882

4.  Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.

Authors:  Ersilia M DeFilippis; Javed Butler; Muthiah Vaduganathan
Journal:  Circ Heart Fail       Date:  2017-11       Impact factor: 8.790

5.  Gaps in Adherence to Guideline-Directed Medical Therapy Before Defibrillator Implantation.

Authors:  Gregg C Fonarow; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2016-03-08       Impact factor: 24.094

6.  A Heart Team approach to contemporary device decision-making in heart failure.

Authors:  Anubodh S Varshney; Jagmeet P Singh; Muthiah Vaduganathan
Journal:  Eur J Heart Fail       Date:  2022-02-13       Impact factor: 15.534

7.  AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocol.

Authors:  Valentina Kutyifa; Mary W Brown; Christopher A Beck; Scott McNitt; Crystal Miller; Karlene Cox; Wojciech Zareba; Spencer Z Rosero; Marye J Gleva; Jeanne E Poole
Journal:  Heart Rhythm O2       Date:  2020-11-10

8.  Representativeness of the GALACTIC-HF Clinical Trial in Patients Having Heart Failure With Reduced Ejection Fraction.

Authors:  Matthew T Mefford; Sandra Y Koyama; Justine De Jesus; Rong Wei; Heidi Fischer; Teresa N Harrison; Pauline Woo; Kristi Reynolds
Journal:  J Am Heart Assoc       Date:  2022-03-24       Impact factor: 6.106

9.  Geographic and Temporal Variation in Cardiac Implanted Electric Devices to Treat Heart Failure.

Authors:  Laura A Hatfield; Daniel B Kramer; Rita Volya; Matthew R Reynolds; Sharon-Lise T Normand
Journal:  J Am Heart Assoc       Date:  2016-07-28       Impact factor: 5.501

10.  The Burden of Cardiovascular Diseases Among US States, 1990-2016.

Authors:  Gregory A Roth; Catherine O Johnson; Kalkidan Hassen Abate; Foad Abd-Allah; Muktar Ahmed; Khurshid Alam; Tahiya Alam; Nelson Alvis-Guzman; Hossein Ansari; Johan Ärnlöv; Tesfay Mehari Atey; Ashish Awasthi; Tadesse Awoke; Aleksandra Barac; Till Bärnighausen; Neeraj Bedi; Derrick Bennett; Isabela Bensenor; Sibhatu Biadgilign; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Kairat Davletov; Samath Dharmaratne; Eric L Ding; Manisha Dubey; Emerito Jose Aquino Faraon; Talha Farid; Maryam S Farvid; Valery Feigin; João Fernandes; Joseph Frostad; Alemseged Gebru; Johanna M Geleijnse; Philimon Nyakauru Gona; Max Griswold; Gessessew Bugssa Hailu; Graeme J Hankey; Hamid Yimam Hassen; Rasmus Havmoeller; Simon Hay; Susan R Heckbert; Caleb Mackay Salpeter Irvine; Spencer Lewis James; Dube Jara; Amir Kasaeian; Abdur Rahman Khan; Sahil Khera; Abdullah T Khoja; Jagdish Khubchandani; Daniel Kim; Dhaval Kolte; Dharmesh Lal; Anders Larsson; Shai Linn; Paulo A Lotufo; Hassan Magdy Abd El Razek; Mohsen Mazidi; Toni Meier; Walter Mendoza; George A Mensah; Atte Meretoja; Haftay Berhane Mezgebe; Erkin Mirrakhimov; Shafiu Mohammed; Andrew Edward Moran; Grant Nguyen; Minh Nguyen; Kanyin Liane Ong; Mayowa Owolabi; Martin Pletcher; Farshad Pourmalek; Caroline A Purcell; Mostafa Qorbani; Mahfuzar Rahman; Rajesh Kumar Rai; Usha Ram; Marissa Bettay Reitsma; Andre M N Renzaho; Maria Jesus Rios-Blancas; Saeid Safiri; Joshua A Salomon; Benn Sartorius; Sadaf Ghajarieh Sepanlou; Masood Ali Shaikh; Diego Silva; Saverio Stranges; Rafael Tabarés-Seisdedos; Niguse Tadele Atnafu; J S Thakur; Roman Topor-Madry; Thomas Truelsen; E Murat Tuzcu; Stefanos Tyrovolas; Kingsley Nnanna Ukwaja; Tommi Vasankari; Vasiliy Vlassov; Stein Emil Vollset; Tolassa Wakayo; Robert Weintraub; Charles Wolfe; Abdulhalik Workicho; Gelin Xu; Simon Yadgir; Yuichiro Yano; Paul Yip; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Ben Zipkin; Ashkan Afshin; Emmanuela Gakidou; Stephen S Lim; Ali H Mokdad; Mohsen Naghavi; Theo Vos; Christopher J L Murray
Journal:  JAMA Cardiol       Date:  2018-05-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.